Market size KRW 40 billion -> KRW 35 billion
The aspirin + clopidogrel combination market started to wither before it even bloomed.
According to UBIST, the combined prescription amount of aspirin + clopidogrel complex drugs, which reached KRW 40 billion in 2019, has decreased significantly to KRW 35 billion last year.
All of the large products recorded more than KRW 1 billion in prescription in 2019 had a degrowth trend.
Especially, Clopirin (Jeil Pharmaceutical), Plavix A (Sanofi), and Superpirin (Myung In Pharmaceutical), which formed the leading group with KRW 8 billion prescription together, fell below KRW 8 billion.
Clopirin fell only 3.8%, with KRW 7.9 billion in prescription, but Plavix A and Superpirin plunged 12.1% and 22.3% from KRW 8.2 billion to KRW 7.2 billion and KRW 8.9 billion to KRW 6.9 billion.
Superpirin once became a blockbuster in 2018 but has been pushed back to KRW 6 billion mark, losing its strength in the leading competition.
Plavix A also quickly expanded its performance after entering the market belatedly, narrowing its gap with Clopirin by KRW 40 million in 2019, but the gap widened by more than KRW 700 million last year due to sluggish performance.
Following the leading group, Closone (HK inno.N) also shrunk 17.8% from KRW 5.7 billion to KRW 4.7 billion.
The prescription for Clavixin Duo (Korea United Pharm) decreased by 18.7% from KRW 4.3 billion to KRW 3.5 billion, and Pidogul A (JinYang Pharm) tumbled 36.3% from KRW 2.3 billion to KRW 1.5 billion.
Meanwhile, Aspido (Korea Global Pharm) has risen to KRW 1 billion mark, while Clopigrel Duo (Celltrion Pharm) and Copregrel (Chong Kun Dang Pharmaceutical) have expanded from KRW 300 million to KRW 800 million mark and KRW 300 million to KRW 400 million mark, showing opposition trend movement to major products.
